The outcome of Daclatasvir and low dose Sofosbuvir therapy in end-stage renal disease patients with hepatitis C virus infection

M.  Mostafi; M.  Jabin; Z.  Chowdhury; M.U.  Khondoker; S.M.   Ali; R.  Tamanna; R.  Rezwan; S.B.  Alomgir

doi:10.31450/ukrjnd.2(66).2020.01

M. Mostafi Gonoshasthaya Somaj Vittik Medical College https://orcid.org/0000-0002-5075-2783
M. Jabin Gonoshasthaya Nagar Hospital https://orcid.org/0000-0002-4639-862X
Z. Chowdhury Gonoshasthaya Somaj Vittik Medical College https://orcid.org/0000-0003-2668-4829
M.U. Khondoker Gonoshasthaya Nagar Hospital https://orcid.org/0000-0003-1021-4435
S.M. Ali Gonoshasthaya Somaj Vittik Medical College https://orcid.org/0000-0002-3945-024X
R. Tamanna Gonoshasthaya Nagar Hospital https://orcid.org/0000-0003-4901-6858
R. Rezwan Gonoshasthaya Nagar Hospital https://orcid.org/0000-0001-9071-4864
S.B. Alomgir Gonoshasthaya Nagar Hospital https://orcid.org/0000-0002-8282-389X

DOI: https://doi.org/10.31450/ukrjnd.2(66).2020.01

Keywords: hepatitis C virus infection, direct-acting antiviral therapy, chronic kidney disease, end-stage renal disease.

Abstract

Rapid progression of chronic kidney disease (CKD) is seen in patients with hepatitis C virus (HCV) infection compared with uninfected patients. Despite the high efficacy of direct-acting antivirals (DAAVs), their cost represents a limiting factor to their use in developing countries.

Aim. This study aimed to evaluate the efficacy of low dose Sofosbuvir along with Daclatasvir in the management of HCV infection in end-stage renal disease (ESRD) patients.

Methods. A total of 82 HCV positive patients on ESRD were included in this study. The patients were observed for six months without antiviral drugs. Patients who remained seropositive were divided into two groups. The first group included 26 (37%) patients who were treated with half-dose Sofosbuvir 200 mg and Daclatasvir 60 mg and the second group consisted of 44 (63%) patients who have been treated with full-dose Sofosbuvir 400 mg and Velpatasvir 100 mg irrespective of HCV infection genotype for 12 weeks also.

Results. 12 (14%) patients became seronegative spontaneously. All patients (100%) of both groups achieved sustained virological response with undetectable HCV RNA in 12 weeks of the treatment. There were nonsignificant gastrointestinal side effects in the full dose Sofosbuvir group. All patients tolerated the DAAs well. No patient discontinued antiviral therapy due to side effects

Conclusion. In this study, the spontaneous seroconversion of HCV was 14%. Low-dose Sofosbuvir along with Daclatasvir was safe and as effective as full-dose Sofosbuvir and Velpatasvir in the treatment of HCV in ESRD patients. Low-dose Sofosbuvir regimen can be recommended for HCV infection treatment in ESRD patients.

Downloads

Download data is not yet available.

References

Fissell RB, Bragg-Gresham JL, Woods JD, Jadoul M, Gillespie B, Hedderwick SA, Rayner HC, Greenwood RN, Akiba T, Young EW. Patterns of hepatitis C prevalence and seroconversion in hemodialysis units from three continents: the DOPPS. Kidney Int. 2004;65:2335–2342. doi: 10.1111/j.1523-1755.2004.00649.x

Fabrizi F, Dixit V, Dixit V. Impact of hepatitis C on survival in dialysis patients: A link with cardiovascular mortality? J Viral Hepat. 2012;19:601–607. doi: 10.1111/j.1365-2893.2012.01633.x

AASLD-IDSA. Recommendations for testing, managing, and treating hepatitis C. [cited 2018 Feb 2]. Available from: https://www.hcvguidelines.org. Accessed 26 Jan 2018.

Roth D, Nelson D, Bruchfeld A, Liapakis A, Silva M, Monsour H Jr, Martin P, Pol S, Londoño MC, et al. Grazoprevir plus elbasvir in treatment-naive and treatment experienced patients with hepatitis C virus genotype 1 infection and stage 4-5 chronic kidney disease (the C-SURFER study): A combination phase 3 study. Lancet. 2015;386:1537–1545. doi: 10.1016/S0140-6736(15)00349-9.

Pockros PJ, Reddy KR, Mantry PS, Cohen E, Bennett M, Sulkowski MS, Bernstein DE, et al. Efficacy of Direct-Acting Antiviral Combination for Patients With Hepatitis C Virus Genotype 1 Infection and Severe Renal Impairment or End-Stage Renal Disease. Gastroenterology. 2016;150(7):1590-1598. doi: 10.1053/j.gastro.2016.02.078.

Gane E, Lawitz E, Pugatch D, Papatheodoridis G, Bräu N, Brown A, et al. Glecaprevir and Pibrentasvir in patients with HCV and severe renal impairment. N Engl J Med 2017;377:1448-1455. doi: 10.1056/NEJMoa1704053

Duseja A, Choudhary NS, Gupta S, Dhiman RK, Chawla Y, Sakhuja V. Treatment of chronic hepatitis C in end stage renal disease: experience at a tertiary care centre. Trop Gastroenterol. 2012;33(3):189–192. doi:10.7869/tg.2012.47

Gordon CE, Uhlig K, Lau J, Schmid CH, Levey AS, Wong JB. Interferon treatment in hemodialysis patients with chronic hepatitis C virus infection: a systematic review of the literature and meta-analysis of treatment efficacy and harms. Am J Kidney Dis. 2008;51(2):263–277. doi:10.1053/j.ajkd.2007.11.003

Alavian SM, Tabatabaei SV. Meta-analysis of factors associated with sustained viral response in patients on hemodialysis treated with standard or pegylated interferon for hepatitis C infection. Iran J Kidney Dis. 2010;4(3):181–194.

Okoh EJ, Bucci JR, Simon JF, Harrison SA. HCV in patients with end-stage renal disease. Am J Gastroenterol. 2008;103(8):2123–2134. doi:10.1111/j.1572-0241.2008.01981.x

Carrion AF, Fabrizi F, Martin P. Should ribavirin be used to treat hepatitis C in dialysis patients?. Semin Dial. 2011;24(3):272–274. doi:10.1111/j.1525-139X.2011.00851.x

Liu CH, Huang CF, Liu CJ, Dai CY, Liang CC, Huang JF, Hung PH, Tsai HB, Tsai MK, Chen SI, Lin JW, et al. Pegylated interferon-α2a with or without low-dose ribavirin for treatment-naive patients with hepatitis C virus genotype 1 receiving hemodialysis: a randomized trial. Ann Intern Med. 2013;159(11):729-38. doi: 10.7326/0003-4819-159-11-201312030-00005.

AASLD/IDSA HCV Guidance Panel. Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus. Hepatology. 2015;62(3):932–954. doi:10.1002/hep.27950.

Cornpropst M, Denning J, Clemons D, et al. The effect of renal impairment and end stage renal disease on the single-dosepharmacokinetics of PSI-7977 [abstract 1101]. 47th Annual Meeting of the European Association for the Study of the Liver (EASL), April 18-22, 2012, Barcelona. doi: 10.1016/S0168-8278(12)61113-1

Smolders EJ, de Kanter CT, van Hoek B, Arends JE, Drenth JP, Burger DM. Pharmacokinetics, Efficacy, and Safety of Hepatitis C Virus Drugs in Patients with Liver and/or Renal Impairment. Drug Saf. 2016;39(7):589–611. doi:10.1007/s40264-016-0420-2.

Choudhary NS, Kumar A, Bodh V, Bansal SB, Sharma R, Jain M, Saigal S, Saraf N. Efficacy and safety of sofosbuvir-based regimens in chronic hepatitis C patients on dialysis. Indian J Gastroenterol. 2017;36(2):113-116. doi: 10.1007/s12664-017-0735-7.

Saxena V, Koraishy FM, Sise ME, Lim JK, Schmidt M, Chung RT, Liapakis A, Nelson DR, Fried MW, Terrault NA; HCV-TARGET. Safety and efficacy of sofosbuvir-containing regimens in hepatitis C-infected patients with impaired renal function. Liver Int. 2016;36(6):807-16. doi: 10.1111/liv.13102.

Singh T, Guirguis J, Anthony S, Rivas J, Hanouneh IA, Alkhouri N. Sofosbuvir-based treatment is safe and effective in patients with chronic hepatitis C infection and end stage renal disease: a case series. Liver Int. 2016;36(6):802–806. doi:10.1111/liv.13078.

European Association for the Study of the Liver. EASL Recommendations on Treatment of Hepatitis C 2016. J Hepatol. 2017;66(1):153–194. doi:10.1016/j.jhep.2016.09.001

EMA. Daklinza product information. 2015. Avaible from: https://www.ema.europa.eu/en/documents/product-information/daklinza-epar-product-information_en.pdf

Garimella T, Wang R, Luo WL, Hwang C, Sherman D, Kandoussi H, Marbury TC, Alcorn H, Bertz R, Bifano M. Single-dose pharmacokinetics and safety of daclatasvir in subjects with renal function impairment. Antivir Ther. 2015;20(5):535-43. doi: 10.3851/IMP2941.

Taneja S, Duseja A, De A, Mehta M, Ramachandran R, Kumar V, Kohli HS, Gupta KL, Dhiman RK, Chawla Y. Low-Dose Sofosbuvir Is Safe and Effective in Treating Chronic Hepatitis C in Patients with Severe Renal Impairment or End-Stage Renal Disease. Dig Dis Sci. 2018 May;63(5):1334-1340. doi: 10.1007/s10620-018-4979-6.

Choudhary NS, Kumar A, Bodh V, Bansal SB, Sharma R, Jain M, Saigal S, Saraf N. Efficacy and safety of sofosbuvir-based regimens in chronic hepatitis C patients on dialysis. Indian J Gastroenterol. 2017 Mar;36(2):113-116. doi: 10.1007/s12664-017-0735-7.

Desnoyer A. Sofosbuvir in hemodialysis: 400mg daily of only the day of hemodialysis? [abstract no. 19]. 16th international workshop of clincial pharmacology of HIV and hepatitis therapy, 26 May 2015, Washington, DC.

Gane EJ, Robson RA, Bonacine M, et al. Safety, antiviral efficacy, and pharmacokinetics of sofosbuvir in patients with severe renal impairment. In: 65th annual meeting of the American association for the study of liver diseases, 7 Nov 2014. Boston, MA; 2014.

Bhamidimarri KR, Czul F, Peyton A, Levy C, Hernandez M, Jeffers L, Roth D, Schiff E, O'Brien C, Martin P. Safety, efficacy and tolerability of half-dose sofosbuvir plus simeprevir in treatment of Hepatitis C in patients with end stage renal disease. J Hepatol. 2015;63(3):763-5. doi: 10.1016/j.jhep.2015.06.004.

Sperl J, Frankova S, Kreidlova M, Merta D, Tothova M, Spicak J. Combination of sofosbuvir and daclatasvir in the treatment of genotype 3 chronic hepatitis C virus infection in patients on maintenance hemodialysis. Ther Clin Risk Manag. 2017;13:733–738. doi:10.2147/TCRM.S133983

Li M, Chen J, Fang Z, Li Y, Lin Q. Sofosbuvir-based regimen is safe and effective for hepatitis C infected patients with stage 4-5 chronic kidney disease: a systematic review and meta-analysis. Virol J. 2019;16(1):34. doi:10.1186/s12985-019-1140-x

Foster GR, Afdhal N, Roberts SK, Brau N, Gane EJ, Pianko S, et al. Sofosbuvir and velpatasvir for HCV genotype 2 and 3 infection. N Engl J Med. 2015;373(27):2608–17. doi:10.1056/ NEJMoa1512612.

Feld JJ, Jacobson IM, Hezode C, Asselah T, Ruane PJ, Gruener N, et al. Sofosbuvir and velpatasvir for HCV genotype 1, 2, 4, 5, and 6 infection. N Engl J Med. 2015;373(27):2599–607. doi:10. 1056/NEJMoa1512610.

Mogalian E, German P, Yang CY, Moorehead L, Brainard D, McNally J, et al. Evaluation of transporter and cytochrome P450mediated drug-drug interactions between pan-genotypic HCV NS5A inhibitor GS-5816 and phenotypic probe drugs [abstract O_07]. 15th international workshop on clinical pharmacology of HIV & hepatitis therapy, 19–21 May 2014, Washington, DC.

Borgia SM, Dearden J, Yoshida EM, Shafran SD, Brown A, Ben-Ari Z, Cramp ME, Cooper C, et al. Sofosbuvir/velpatasvir for 12 weeks in hepatitis C virus-infected patients with end-stage renal disease undergoing dialysis. J Hepatol. 2019;71(4):660-665. doi: 10.1016/j.jhep.2019.05.028.